Nkarta, Inc.
NKTXHealthcare|Biotechnology|US
$1.73
+0.16 (+10.19%)
Tangible Book / Share
$2.89
Cash / Share
$2.10
About
Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes natural killer cell therapies for cancer and autoimmune disease treatment. Its lead product candidate is NKX019, a chimeric antigen receptor-natural killer (CAR NK) targeting the CD19 antigen, which is in Phase 1 clinical trial for the treatment of lupus nephritis; systemic sclerosis; idiopathic inflammatory myopathy; and antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, as well as for systemic lupus erythematosus and myasthenia gravis. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.
Stock Price
-12.2%(1Y)
1M
-22.1%
3M
-28.2%
6M
-45.8%
YTD
-6.5%
1Y
-11.7%
3Y
-19.5%
5Y
-90.2%
Pipeline Summary
5 total trials5
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
Active: 2Recruiting: 2By Invitation: 1
Active Trials (4)
NKX101, Intravenous Allogeneic CAR NK Cells, in Adults With AML or MDS
NCT04623944Relapsed/Refractory AML
Phase 1Active
Enrollment: 61 participants
A Phase 1/2 Study of NKX019 in Subjects With Immune-Mediated Diseases (Ntrust-2)
NCT06733935Systemic Sclerosis
Phase 1Phase 2Recruiting
Enrollment: 240 participants
A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
NCT06557265Lupus Nephritis
Phase 1Phase 2Recruiting
Enrollment: 120 participants
NKX019, Intravenous Allogeneic Chimeric Antigen Receptor Natural Killer Cells (CAR NK), in Adults With B-cell Cancers
NCT05020678Lymphoma, Non-Hodgkin
Phase 1Active
Enrollment: 150 participants
Key Facts
Market Cap$123.9M
Employees108 (-31% YoY)
CEOPaul J. Hastings
IPO DateJul 10, 2020
Beta0.97
52-Week Range$1.48 – $3.72
Avg Volume795,303
ExchangeNASDAQ
Websitenkartatx.com
Ownership
Float80.4%
Shares Outstanding71.6M
Recent Insider Trades
HASTINGS PAUL JSELL
Jun 18, 20261,776 shares @ $2.71
RA CAPITAL MANAGEMENT, L.P.AWARD
Jun 10, 202637,000 shares @ $2.46
Behbahani AliAWARD
Jun 10, 202637,000 shares @ $2.46
George SimeonAWARD
Jun 10, 202637,000 shares @ $2.46
Vratsanos GeorgeAWARD
Jun 10, 202637,000 shares @ $2.46
Peers
Recent News
Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026
Nov 6, 2026 · globenewswire.com
Nkarta Reports Third Quarter 2026 Financial Results and Provides Business Update
Nov 5, 2026 · globenewswire.com
Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials Advance
Sep 28, 2026 · defenseworld.net
Nkarta Targets ACR 2026 Data Reveal as Outpatient CAR NK Trials Advance
Sep 27, 2026 · marketbeat.com
Nkarta (NASDAQ:NKTX) Stock Falls 3.5% – Here’s Why
Sep 27, 2026 · defenseworld.net
Data last updated: Nov 9, 2026, 04:24 AM